Bioinformatics Market

研究執行與發布：MarketsandMarkets　·　發布日期 2026-07-17　·　488 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

完整報告名稱與涵蓋範圍

Bioinformatics Market by Offering [Software (Genomics, Multiomics, Proteomics), Services (Analysis, Sequencing)], Function (Variant & Structural Analysis), Use Case (Drug Discovery, Biomarker), End User (Pharma & Biotech, CROs) - Global Forecast to 2031

報告摘要

The global bioinformatics market is projected to reach USD 34.41 billion by 2031, up from USD 18.63 billion in 2026, at a CAGR of 13.1% over the forecast period. Rapid growth in genomics research, precision medicine initiatives, and drug discovery programs has significantly increased demand for bioinformatics platforms that store, manage, analyze, and interpret complex biological datasets. Pharmaceutical and biotechnology companies, academic institutions, and healthcare organizations are increasingly adopting integrated bioinformatics solutions to accelerate research, improve clinical decision-making, and optimize therapeutic development. Furthermore, the growing digital transformation of life science research, coupled with rising investments in computational biology and cloud-based bioinformatics platforms, is improving workflow efficiency, enabling large-scale data sharing, and supporting collaborative research across organizations. “End-to-end solutions projected to be the largest software segment in the bioinformatics market” Software-based end-to-end solutions are expected to dominate market share during the forecast period. This dominance is driven by growing demand for integrated platforms that support complete bioinformatics workflows, including biological data acquisition, storage, processing, analysis, visualization, interpretation, and reporting. These comprehensive solutions enable researchers and clinicians to efficiently manage complex genomic, proteomic, transcriptomic, and multi-omics datasets through a single platform, reducing workflow complexity and improving operational efficiency. As the volume and complexity of biological data continue to increase, demand for scalable, integrated bioinformatics platforms is expected to further strengthen the leadership of the end-to-end solutions segment throughout the forecast period. “By sector, medical biotechnology accounted for the major share of the bioinformatics market” Within the sector, medical biotechnology accounted for the largest share, driven by the growing use of bioinformatics across genomics, precision medicine, molecular diagnostics, drug discovery, biomarker identification, and clinical research. The rising prevalence of chronic diseases, cancer, and rare genetic disorders has further accelerated the adoption of bioinformatics solutions to support personalized treatment strategies and advanced molecular diagnostics. In addition, ongoing advances in next-generation sequencing (NGS), artificial intelligence (AI), machine learning, and cloud-based bioinformatics platforms have improved the speed, scalability, and accuracy of biological data analysis. Increasing investments in life science research, precision medicine initiatives, and genomic medicine programs are expected to further reinforce the medical biotechnology segment's leading position throughout the forecast period. “Asia Pacific to witness the fastest growth rate during the forecast period.” The bioinformatics market in Asia Pacific is projected to have the highest CAGR during the forecast period, primarily driven by rising investments in genomics research, precision medicine, and biotechnology across emerging economies such as China, India, Japan, South Korea, and Singapore. Governments in the region are actively supporting genomics and life sciences research through funding initiatives, national genomics programs, and policies that promote digital healthcare and biotechnology innovation. The break-down of primary participants is as mentioned below: • By Company Type - Tier 1: 46%, Tier 2: 34%, and Tier 3: 20% • By Designation - C-level: 35%, Director-level: 25%, and Others: 40% • By Region - North America: 45%, Europe: 30%, Asia Pacific: 20%, Latin America: 3%, and Middle East & Africa: 2%. Thermo Fisher Scientific Inc. (US) & Illumina, Inc. (US) are some of the key players in the bioinformatics market • The study includes an in-depth competitive analysis of these key players in the bioinformatics market, with their company profiles, recent developments, and key market strategies. Research Coverage This research report categorizes the bioinformatics market by offerings (software & bioinformatics services), by function (data analysis, structural & functional analysis, multi-omics integration, clinical interpretation, data visualization & reporting, other functions), by use case (drug discovery & development, precision medicine, clinical diagnostics, biomarker discovery, research & academic applications, other use cases), by sector (medical biotechnology, animal biotechnology, plant biotechnology, environmental biotechnology, forensic biotechnology, other sectors), by end user (pharmaceutical & biotechnology companies, academic and research institutes, hospitals & clinical diagnostic laboratories, contract research organizations (CROs) & contract development and manufacturing organizations (CDMOs), government and public health organizations, other end users), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa). The scope of the report covers detailed information on the major factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the bioinformatics market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, partnerships, agreements, product and service launches, mergers and acquisitions, and recent developments associated with the bioinformatics market. The report also covers a competitive analysis of upcoming startups in the bioinformatics market ecosystem. Reasons to buy this report The report will provide market leaders and new entrants with the closest approximations of revenue figures for the bioinformatics market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to position their businesses more effectively and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. The report provides insights into the following pointers: • Analysis of key drivers (increasing adoption of next-generation sequencing (NGS), growing demand for personalized medicine, rising pharmaceutical and biotechnology R&D expenditure, increasing public and private-sector funding for bioinformatics, increasing adoption of AI and machine learning in the life sciences), restraints (high cost of bioinformatics infrastructure, data privacy, security, and regulatory compliance concerns, shortage of skilled bioinformatics professionals), opportunities (lucrative opportunities in emerging markets, expansion of clinical bioinformatics, adoption of cloud and federated bioinformatics platforms, growth of bioinformatics outsourcing services), and challenges (management of large data volumes, lack of interoperability and multiplatform capabilities, growing competition from in-house development and publicly available tools, integration of multi-omics datasets) • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the bioinformatics market • Market Development: Comprehensive information about lucrative markets – the report analyzes the bioinformatics market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioinformatics market • Competitive Assessment: In-depth assessment of market share, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), among others, in the bioinformatics market.

授權報價

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

目錄 Table of Contents

1 INTRODUCTION 37 1.1 STUDY OBJECTIVES 37 1.2 MARKET DEFINITION 37 1.3 STUDY SCOPE 38 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 38 1.3.2 INCLUSIONS & EXCLUSIONS 39 1.3.3 YEARS CONSIDERED 40 1.3.4 CURRENCY CONSIDERED 41 1.4 STAKEHOLDERS 41 1.5 SUMMARY OF CHANGES 41 2 EXECUTIVE SUMMARY 43 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 43 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 45 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 46 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 47 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 48 3 PREMIUM INSIGHTS 49 3.1 BIOINFORMATICS MARKET OVERVIEW 49 3.2 BIOINFORMATICS MARKET, BY OFFERING & REGION 50 3.3 BIOINFORMATICS MARKET: GEOGRAPHIC SNAPSHOT 50 4 MARKET OVERVIEW 51 4.1 INTRODUCTION 51 4.2 MARKET DYNAMICS 51 4.2.1 DRIVERS 52 4.2.1.1 Increasing adoption of next-generation sequencing (NGS) 52 4.2.1.2 Growing demand for personalized medicine 52 4.2.1.3 Increasing pharmaceutical and biotechnology R&D expenditure 54 4.2.1.4 Increasing public and private-sector funding for bioinformatics 55 4.2.1.5 Increasing adoption of AI and machine learning in life sciences 57 4.2.1.6 Decreasing cost of genome sequencing 58 4.2.2 RESTRAINTS 58 4.2.2.1 High cost of bioinformatics infrastructure 58 4.2.2.2 Data privacy, security, and regulatory compliance concerns 59 4.2.2.3 Shortage of skilled bioinformatics professionals 60 4.2.3 OPPORTUNITIES 60 4.2.3.1 Lucrative opportunities in emerging markets 60 4.2.3.2 Expansion of clinical bioinformatics 61 4.2.3.3 Adoption of cloud and federated bioinformatics platforms 61 4.2.3.4 Growth of bioinformatics outsourcing services 62 4.2.4 CHALLENGES 62 4.2.4.1 Management of large data volumes 62 4.2.4.2 Lack of interoperability and multiplatform capabilities 62 4.2.4.3 Growing competition from in-house development and publicly available tools 63 4.2.4.4 Integration of multiomics datasets 63 4.3 UNMET NEEDS AND WHITE SPACES 64 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 65 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 66 5 INDUSTRY TRENDS 68 5.1 PORTER’S FIVE FORCES ANALYSIS 68 5.1.1 THREAT OF NEW ENTRANTS 69 5.1.2 THREAT OF SUBSTITUTES 69 5.1.3 BARGAINING POWER OF SUPPLIERS 69 5.1.4 BARGAINING POWER OF BUYERS 69 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70 5.2 MACROECONOMIC INDICATORS 70 5.2.1 INTRODUCTION 70 5.2.2 GDP TRENDS AND FORECAST 70 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 71 5.3 VALUE CHAIN ANALYSIS 71 5.3.1 RESEARCH & PRODUCT DEVELOPMENT 72 5.3.2 TECHNOLOGY INFRASTRUCTURE 72 5.3.3 PLATFORM DEVELOPMENT 72 5.3.4 DISTRIBUTION 72 5.3.5 MARKETING & SALES 73 5.3.6 POST-SALE SERVICES 73 5.4 ECOSYSTEM ANALYSIS 73 5.5 PRICING ANALYSIS 74 5.5.1 INDICATIVE PRICING FOR BIOINFORMATICS MARKET, BY OFFERING (2025) 75 5.5.2 INDICATIVE PRICING IN BIOINFORMATICS MARKET, BY REGION (2025) 75 5.6 KEY CONFERENCES AND EVENTS, 2026–2027 76 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 78 5.8 INVESTMENT AND FUNDING SCENARIO 79 5.9 CASE STUDY ANALYSIS 80 5.10 IMPACT OF 2025 US TARIFF –BIOINFORMATICS MARKET 82 5.10.1 INTRODUCTION 82 5.10.2 KEY TARIFF RATES 83 5.10.3 PRICE IMPACT ANALYSIS 84 5.10.4 IMPACT ON COUNTRY/REGION 84 5.10.4.1 US 84 5.10.4.2 Europe 85 5.10.4.3 Asia Pacific 85 5.10.5 IMPACT ON END USERS 85 5.10.5.1 Pharmaceutical & biotechnology companies 85 5.10.5.2 Academic & research institutes 86 5.10.5.3 Hospitals & clinical diagnostic laboratories 86 5.10.5.4 Contract research organizations and contract development & manufacturing organizations 86 5.10.5.5 Government & public health organizations 86 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 87 6.1 KEY EMERGING TECHNOLOGIES 87 6.1.1 NEXT-GENERATION SEQUENCING TECHNOLOGIES 87 6.1.2 ARTIFICIAL INTELLIGENCE & MACHINE LEARNING 88 6.1.3 MULTIOMICS ANALYSIS PLATFORMS 88 6.1.4 VARIANT INTERPRETATION & CLINICAL DECISION SUPPORT 88 6.2 COMPLEMENTARY TECHNOLOGIES 89 6.2.1 GENERATIVE AI FOR BIOINFORMATICS 89 6.2.2 AI-BASED DRUG DISCOVERY PLATFORMS 89 6.2.3 LARGE LANGUAGE MODELS FOR LIFE SCIENCES 89 6.3 ADJACENT TECHNOLOGIES 90 6.3.1 HIGH-PERFORMANCE COMPUTING 90 6.3.2 BIG DATA ANALYTICS 90 6.3.3 BLOCKCHAIN TECHNOLOGY 91 6.3.4 ROBOTICS & LABORATORY AUTOMATION 91 6.4 TECHNOLOGY/PRODUCT ROADMAP 91 6.5 PATENT ANALYSIS 92 6.5.1 PATENT PUBLICATION TRENDS FOR BIOINFORMATICS MARKET 92 6.5.2 BIOINFORMATICS PATENTS: JURISDICTION AND TOP APPLICANT ANALYSIS 93 6.6 FUTURE APPLICATIONS 96 6.6.1 AI-DRIVEN GENOMIC INTERPRETATION & CLINICAL DECISION SUPPORT 96 6.6.2 PRECISION MEDICINE & MULTIOMICS INTEGRATION 96 6.6.3 INTEGRATED BIOINFORMATICS FOR DRUG DISCOVERY & CLINICAL RESEARCH 96 6.7 IMPACT OF GEN AI IN BIOINFORMATICS MARKET 97 6.7.1 INTRODUCTION 97 6.7.2 MARKET POTENTIAL OF AI/GEN AI IN BIOINFORMATICS MARKET 98 6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 99 6.7.3.1 AI-powered genomics for precision medicine at Illumina and Tempus AI 99 6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 100 6.7.4.1 AI in bioinformatics software market 100 6.7.4.2 Next-generation sequencing market 100 6.7.4.3 Drug discovery market 101 6.7.5 USERS READINESS AND IMPACT ASSESSMENT 101 6.7.5.1 User readiness 101 6.7.5.1.1 Pharmaceutical & biotechnology companies 101 6.7.5.1.2 Academic & research institutes 101 6.7.5.1.3 Hospitals & clinical diagnostic laboratories 101 6.7.5.1.4 Contract research organizations and contract development & manufacturing organizations 102 6.7.5.2 Impact assessment 102 6.7.5.2.1 User A: Pharmaceutical & biotechnology companies 102 6.7.5.2.1.1 Implementation 102 6.7.5.2.1.2 Impact 102 6.7.5.2.2 User B: Academic & Research Institutes 102 6.7.5.2.2.1 Implementation 102 6.7.5.2.2.2 Impact 103 6.7.5.2.3 User C: Hospitals & Clinical Diagnostic Laboratories 103 6.7.5.2.3.1 Implementation 103 6.7.5.2.3.2 Impact 103 6.7.5.2.4 User D: Contract research organizations and contract development & manufacturing organizations 103 6.7.5.2.4.1 Implementation 103 6.7.5.2.4.2 Impact 103 7 REGULATORY LANDSCAPE 104 7.1 REGIONAL REGULATIONS AND COMPLIANCE 104 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 7.1.2 REGULATORY FRAMEWORK 108 7.1.2.1 North America 108 7.1.2.2 Europe 109 7.1.2.3 Asia Pacific 110 7.1.2.4 Latin America 110 7.1.2.5 Middle East & Africa 111 7.1.3 INDUSTRY STANDARDS 111 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113 8.1 INTRODUCTION 113 8.2 DECISION-MAKING PROCESS 113 8.3 STAKEHOLDERS AND BUYING EVALUATION CRITERIA 113 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 114 8.3.2 BUYING CRITERIA 115 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 116 8.5 UNMET NEEDS FROM VARIOUS END USERS 117 8.5.1 UNMET NEEDS 117 8.5.2 END USER EXPECTATIONS 119 8.6 MARKET PROFITABILITY 120 9 BIOINFORMATICS MARKET, BY OFFERING 121 9.1 INTRODUCTION 122 9.2 SOFTWARE 122 9.2.1 NICHE POINT SOLUTIONS 124 9.2.1.1 Increasing adoption of NGS and multiomics technologies to boost growth 124 9.2.2 KNOWLEDGE MANAGEMENT TOOLS 125 9.2.2.1 Rising demand for genomic variant interpretation databases 125 9.2.2.2 Generalized knowledge management tools 126 9.2.2.2.1 Development of novel generalized knowledge management tools to drive growth 126 9.2.2.3 Specialized knowledge management tools 127 9.2.2.3.1 Data security and highly reliable information storage systems to support growth 127 9.2.3 END-TO-END SOLUTIONS 129 9.2.3.1 Integration of artificial intelligence (AI) and machine learning (ML) to drive growth 129 9.2.3.2 Genomic solutions 130 9.2.3.2.1 Expansion of precision medicine and genomic diagnostics – segment driver 130 9.2.3.3 Multiomics solutions 132 9.2.3.3.1 Increasing integration of genomics, transcriptomics, proteomics, and metabolomics dataset to drive market 132 9.2.3.4 Chemoinformatics solutions 133 9.2.3.4.1 Increasing investment in R&D to boost segment 133 9.2.3.5 Proteomics solutions 135 9.2.3.5.1 Growing focus on protein biomarker discovery fuels adoption 135 9.2.3.6 Transcriptomics solutions 136 9.2.3.6.1 Rising demand for gene expression analysis accelerates adoption 136 9.2.3.7 Metabolomics solutions 137 9.2.3.7.1 Adoption of LC-MS and GC-MS technologies accelerates segment growth 137 9.2.3.8 Other end-to-end Solutions 138 9.3 SERVICES 139 9.3.1 SEQUENCING & DATA GENERATION 141 9.3.1.1 Increasing adoption of NGS drives demand 141 9.3.2 DATA ANALYSIS & INTERPRETATION 142 9.3.2.1 Growing complexity of multiomics data drives demand 142 9.3.3 DRUG DISCOVERY & TARGET IDENTIFICATION 143 9.3.3.1 Increasing adoption of precision medicine fuels demand 143 9.3.4 DATABASE & DATA MANAGEMENT 145 9.3.4.1 Exponential growth of biological data drives segment 145 9.3.5 CLOUD & MANAGED BIOINFORMATICS 146 9.3.5.1 Increasing adoption of cloud computing accelerates segment growth 146 9.3.6 CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT 147 9.3.6.1 Increasing demand for customized bioinformatics workflows boosts segment 147 9.3.7 OTHER SERVICES 148 10 BIOINFORMATICS MARKET, BY FUNCTION 150 10.1 INTRODUCTION 151 10.2 DATA ANALYSIS 151 10.2.1 SEQUENCE ANALYSIS 153 10.2.1.1 Growing volume of sequencing data drives demand 153 10.2.2 VARIANT ANALYSIS 153 10.2.2.1 Increasing adoption of precision medicine to boost segment 153 10.2.3 GENE EXPRESSION ANALYSIS 154 10.2.3.1 Expanding transcriptomics research drives segment growth 154 10.2.4 OTHER DATA ANALYSIS FUNCTIONS 155 10.3 STRUCTURAL & FUNCTIONAL ANALYSIS 155 10.3.1 GROWING ADOPTION OF STRUCTURE-BASED DRUG DISCOVERY AND PROTEIN MODELING TO BOOST GROWTH 155 10.4 MULTIOMICS INTEGRATION 156 10.4.1 INCREASING INTEGRATION OF MULTIOMICS DATA DRIVES DEMAND FOR ADVANCED BIOINFORMATICS PLATFORMS 156 10.5 CLINICAL INTERPRETATION 157 10.5.1 GROWING ADOPTION OF PRECISION MEDICINE AND CLINICAL GENOMICS IS PROPELS GROWTH 157 10.6 DATA VISUALIZATION & REPORTING 158 10.6.1 INCREASING ADOPTION OF AI-DRIVEN DRUG DISCOVERY AND COMPUTATIONAL CHEMISTRY – KEY SEGMENT DRIVER 158 10.7 OTHER FUNCTIONS 159 11 BIOINFORMATICS MARKET, BY USE CASE 161 11.1 INTRODUCTION 162 11.2 DRUG DISCOVERY & DEVELOPMENT 162 11.2.1 GROWING PHARMACEUTICAL R&D INVESTMENTS DRIVE GROWTH 162 11.3 PRECISION MEDICINE 163 11.3.1 INCREASING DEMAND FOR PERSONALIZED TREATMENT STRATEGIES TO BOOST SEGMENT 163 11.4 CLINICAL DIAGNOSTICS 164 11.4.1 GROWING ADOPTION OF GENOMIC TESTING – KEY DRIVER 164 11.5 BIOMARKER DISCOVERY 165 11.5.1 GROWING FOCUS ON PRECISION MEDICINE AND COMPANION DIAGNOSTICS TO BOOST SEGMENT 165 11.6 RESEARCH & ACADEMIC APPLICATIONS 166 11.6.1 INCREASING INVESTMENTS IN LIFE SCIENCE RESEARCH PROPEL SEGMENT GROWTH 166 11.7 OTHER USE CASES 167 12 BIOINFORMATICS MARKET, BY SECTOR 169 12.1 INTRODUCTION 170 12.2 MEDICAL BIOTECHNOLOGY 170 12.2.1 EXPANSION OF GENOMIC DIAGNOSTICS, MOLECULAR TESTING, AND PERSONALIZED HEALTHCARE TO DRIVE SEGMENT 170 12.3 ANIMAL BIOTECHNOLOGY 171 12.3.1 INCREASING ADOPTION OF PRECISION LIVESTOCK FARMING AND VETERINARY GENOMICS TO PROPEL GROWTH 171 12.4 PLANT BIOTECHNOLOGY 172 12.4.1 GROWING DEMAND FOR CLIMATE-RESILIENT AND HIGH-YIELD CROPS TO BOOST SEGMENT 172 12.5 ENVIRONMENTAL BIOTECHNOLOGY 173 12.5.1 INCREASING ADOPTION OF ENVIRONMENTAL DNA (EDNA) AND METAGENOMICS BOOSTS GROWTH 173 12.6 FORENSIC BIOTECHNOLOGY 174 12.6.1 INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING AND FORENSIC GENOMICS TO DRIVE SEGMENT 174 12.7 OTHER SECTORS 175 13 BIOINFORMATICS MARKET, BY END USER 177 13.1 INTRODUCTION 178 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 178 13.2.1 INCREASING PHARMACEUTICAL R&D INVESTMENTS AND ADOPTION OF ADVANCED COMPUTATIONAL TECHNOLOGIES 178 13.3 ACADEMIC & RESEARCH INSTITUTES 180 13.3.1 GROWING GOVERNMENT FUNDING FOR BIOMEDICAL RESEARCH DRIVES SEGMENT 180 13.4 HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES 181 13.4.1 INCREASED APPLICATIONS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH 181 13.5 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS 182 13.5.1 INCREASING OUTSOURCING OF DRUG DEVELOPMENT AND GROWING DEMAND FOR SPECIALIZED COMPUTATIONAL EXPERTISE 182 13.6 GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS 183 13.6.1 INCREASING INVESTMENTS IN GENOMIC SURVEILLANCE AND PUBLIC HEALTH INFORMATICS 183 13.7 OTHER END USERS 184 14 BIOINFORMATICS MARKET, BY REGION 186 14.1 INTRODUCTION 187 14.2 NORTH AMERICA 187 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 188 14.2.2 US 194 14.2.2.1 Strong government support and rapid advances in genomics and AI drive market 194 14.2.3 CANADA 200 14.2.3.1 Increasing government investments in genomics and national bioinformatics infrastructure 200 14.3 EUROPE 206 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 206 14.3.2 GERMANY 212 14.3.2.1 Strong government investments in precision medicine and expanding AI-enabled bioinformatics research 212 14.3.3 UK 218 14.3.3.1 Strategic initiatives and funding for genomics research to support market growth 218 14.3.4 FRANCE 224 14.3.4.1 Market driven by national genomics programs and AI-enabled biomedical research 224 14.3.5 ITALY 229 14.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology 229 14.3.6 SPAIN 235 14.3.6.1 Growing focus on advancements in personalized medicine to support market growth 235 14.3.7 REST OF EUROPE 240 14.4 ASIA PACIFIC 245 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 246 14.4.2 CHINA 252 14.4.2.1 Expansion of national genomic data infrastructure drives market 252 14.4.3 JAPAN 257 14.4.3.1 Rising number of collaborations in bioinformatics to drive market 257 14.4.4 INDIA 263 14.4.4.1 Government and private initiatives for genomics projects to propel market 263 14.4.5 AUSTRALIA 268 14.4.5.1 Increased genetic research to support market growth 268 14.4.6 SOUTH KOREA 273 14.4.6.1 National biomedical data integration and AI-driven precision medicine accelerate market 273 14.4.7 REST OF ASIA PACIFIC 278 14.5 LATIN AMERICA 284 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 285 14.5.2 BRAZIL 290 14.5.2.1 Increased government investments in genomics advancements to drive market 290 14.5.3 MEXICO 296 14.5.3.1 Rising demand for chronic disease treatment to support growth 296 14.5.4 REST OF LATIN AMERICA 301 14.6 MIDDLE EAST & AFRICA 307 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 307 14.6.2 GCC COUNTRIES 313 14.6.2.1 Saudi Arabia 318 14.6.2.1.1 Growing healthcare expenditure to boost market growth 318 14.6.2.2 UAE 324 14.6.2.2.1 Collaborations to advance genome sequencing and market growth 324 14.6.2.3 Rest of GCC 329 14.6.3 SOUTH AFRICA 334 14.6.3.1 Growing focus on precision medicine to propel market 334 14.6.4 REST OF MIDDLE EAST & AFRICA 339 15 COMPETITIVE LANDSCAPE 345 15.1 OVERVIEW 345 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 345 15.3 REVENUE ANALYSIS, 2021–2025 348 15.4 MARKET SHARE ANALYSIS, 2025 348 15.5 BRAND COMPARISON 352 15.6 COMPANY VALUATION AND FINANCIAL METRICS 353 15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 354 15.7.1 STARS 354 15.7.2 EMERGING LEADERS 354 15.7.3 PERVASIVE PLAYERS 354 15.7.4 PARTICIPANTS 354 15.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 356 15.7.5.1 Company footprint 356 15.7.5.2 Region footprint 357 15.7.5.3 Offering footprint 358 15.7.5.4 Function footprint 359 15.7.5.5 Use case footprint 360 15.7.5.6 End user footprint 361 15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 362 15.8.1 PROGRESSIVE COMPANIES 362 15.8.2 RESPONSIVE COMPANIES 362 15.8.3 DYNAMIC COMPANIES 362 15.8.4 STARTING BLOCKS 362 15.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 364 15.8.5.1 List of startups/SMES 364 15.8.5.2 Competitive benchmarking of Startups/SMEs 365 15.9 COMPETITIVE SCENARIO 365 15.9.1 PRODUCT LAUNCHES & ENHANCEMENTS 365 15.9.2 DEALS 367 15.9.3 EXPANSIONS 369 15.9.4 OTHER DEVELOPMENTS 370 16 COMPANY PROFILES 371 16.1 KEY COMPANIES 371 16.1.1 THERMO FISHER SCIENTIFIC INC. 371 16.1.1.1 Business overview 371 16.1.1.2 Products/Services offered 373 16.1.1.3 Recent developments 375 16.1.1.3.1 Product launches 375 16.1.1.3.2 Deals 375 16.1.1.3.3 Expansions 376 16.1.1.4 MnM view 376 16.1.1.4.1 Key strengths 376 16.1.1.4.2 Strategic choices 376 16.1.1.4.3 Weaknesses and competitive threats 377 16.1.2 ILLUMINA, INC. 378 16.1.2.1 Business overview 378 16.1.2.2 Products/Services offered 379 16.1.2.3 Recent developments 380 16.1.2.3.1 Product launches 380 16.1.2.3.2 Deals 381 16.1.2.3.3 Expansions 384 16.1.2.4 MnM view 384 16.1.2.4.1 Key strengths 384 16.1.2.4.2 Strategic choices 385 16.1.2.4.3 Weaknesses and competitive threats 385 16.1.3 QIAGEN N.V. 386 16.1.3.1 Business overview 386 16.1.3.2 Products/services offered 387 16.1.3.3 Recent developments 389 16.1.3.3.1 Product launches & enhancements 389 16.1.3.3.2 Deals 390 16.1.3.3.3 Other developments 391 16.1.3.3.4 Expansions 392 16.1.3.4 MnM view 392 16.1.3.4.1 Key strengths 392 16.1.3.4.2 Strategic choices 392 16.1.3.4.3 Weaknesses and competitive threats 392 16.1.4 AGILENT TECHNOLOGIES, INC. 393 16.1.4.1 Business overview 393 16.1.4.2 Products/Services offered 394 16.1.4.3 Recent developments 395 16.1.4.3.1 Deals 395 16.1.4.4 MnM view 396 16.1.4.4.1 Key strengths 396 16.1.4.4.2 Strategic choices 396 16.1.4.4.3 Weaknesses and competitive threats 396 16.1.5 F. HOFFMANN-LA ROCHE LTD. 397 16.1.5.1 Business overview 397 16.1.5.2 Products/Services offered 398 16.1.5.3 Recent developments 399 16.1.5.3.1 Product launches 399 16.1.5.3.2 Deals 399 16.1.5.3.3 Other developments 400 16.1.5.4 MnM view 400 16.1.5.4.1 Key strengths 400 16.1.5.4.2 Strategic choices 400 16.1.5.4.3 Weaknesses and competitive threats 400 16.1.6 REVVITY, INC. 401 16.1.6.1 Business overview 401 16.1.6.2 Products/Services offered 402 16.1.6.3 Recent developments 403 16.1.6.3.1 Product launches 403 16.1.6.3.2 Deals 404 16.1.6.3.3 Expansions 405 16.1.7 EUROFINS SCIENTIFIC 406 16.1.7.1 Business overview 406 16.1.7.2 Products/services offered 407 16.1.7.3 Recent developments 408 16.1.7.3.1 Deals 408 16.1.7.3.2 Expansions 409 16.1.8 BGI GENOMICS 410 16.1.8.1 Business overview 410 16.1.8.2 Products/services offered 410 16.1.8.3 Recent developments 412 16.1.8.3.1 Deals 412 16.1.9 WATERS CORPORATION 413 16.1.9.1 Business overview 413 16.1.9.2 Products/services offered 414 16.1.10 DNANEXUS, INC. 415 16.1.10.1 Business overview 415 16.1.10.2 Products/services offered 415 16.1.10.3 Recent developments 416 16.1.10.3.1 Product launches 416 16.1.10.3.2 Deals 417 16.1.10.3.3 Other developments 417 16.1.11 OXFORD NANOPORE TECHNOLOGIES PLC 418 16.1.11.1 Business overview 418 16.1.11.2 Products/Services offered 419 16.1.11.3 Recent developments 420 16.1.11.3.1 Deals 420 16.1.11.3.2 Expansions 421 16.1.12 10X GENOMICS 422 16.1.12.1 Business overview 422 16.1.12.2 Products/Services offered 423 16.1.12.3 Recent developments 424 16.1.12.3.1 Deals 424 16.1.13 PACBIO 426 16.1.13.1 Business overview 426 16.1.13.2 Products/Services offered 427 16.1.13.3 Recent developments 428 16.1.13.3.1 Product launches 428 16.1.13.3.2 Deals 428 16.1.13.3.3 Expansions 429 16.1.14 SIEMENS AG 430 16.1.14.1 Business overview 430 16.1.14.2 Products/Services offered 431 16.1.14.3 Recent developments 432 16.1.14.3.1 Product launches 432 16.1.14.3.2 Deals 433 16.1.14.3.3 Other developments 434 16.1.15 SOPHIA GENETICS 435 16.1.15.1 Business overview 435 16.1.15.2 Products/Services offered 436 16.1.15.3 Recent developments 437 16.1.15.3.1 Product Launches 437 16.1.15.3.2 Deals 437 16.1.15.3.3 Other developments 439 16.1.16 EXCELRA 440 16.1.16.1 Business overview 440 16.1.16.2 Products/Services offered 440 16.1.16.3 Recent developments 441 16.1.16.3.1 Product Enhancement 441 16.1.16.3.2 Deals 442 16.1.17 GENEWIZ (AZENTA LIFE SCIENCES) 443 16.1.17.1 Business overview 443 16.1.17.2 Products/Services offered 444 16.1.17.3 Recent developments 445 16.1.17.3.1 Deals 445 16.1.17.3.2 Other developments 445 16.1.18 ONTOFORCE 446 16.1.18.1 Business overview 446 16.1.18.2 Products/Services offered 446 16.1.18.3 Recent developments 447 16.1.18.3.1 Product launches & enhancements 447 16.1.18.3.2 Deals 448 16.1.19 VELSERA INC. 449 16.1.19.1 Business overview 449 16.1.19.2 Products/Services offered 449 16.1.19.3 Recent developments 450 16.1.19.3.1 Deals 450 16.1.20 SEQERA 451 16.1.20.1 Business overview 451 16.1.20.2 Products/Services offered 451 16.1.20.3 Recent developments 452 16.1.20.3.1 Product launches & enhancement 452 16.1.20.3.2 Deals 453 16.1.20.3.3 Other developments 453 16.2 OTHER PLAYERS 454 16.2.1 DNASTAR 454 16.2.2 FIOS GENOMICS 455 16.2.3 DEEP GENOMICS 456 16.2.4 PSOMAGEN 457 16.2.5 SOURCE BIOSCIENCE 458 17 RESEARCH METHODOLOGY 460 17.1 RESEARCH APPROACH 460 17.1.1 SECONDARY RESEARCH 461 17.1.1.1 Key data from secondary sources 462 17.1.2 PRIMARY RESEARCH 463 17.1.2.1 Key data from primary sources 464 17.1.2.2 Breakdown of primaries 465 17.1.2.3 Insights from primary experts 466 17.2 RESEARCH METHODOLOGY DESIGN 466 17.3 MARKET SIZE ESTIMATION 468 17.4 MARKET BREAKDOWN DATA TRIANGULATION 473 17.5 MARKET SHARE ESTIMATION 475 17.6 STUDY ASSUMPTIONS 475 17.7 RESEARCH LIMITATIONS 476 17.7.1 METHODOLOGY-RELATED LIMITATIONS 476 17.7.2 SCOPE-RELATED LIMITATIONS 476 17.8 RISK ASSESSMENT 476 18 APPENDIX 477 18.1 DISCUSSION GUIDE 477 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 484 18.3 CUSTOMIZATION OPTIONS 486 18.4 RELATED REPORTS 486 18.5 AUTHOR DETAILS 487

圖表清單 List of Tables & Figures

TABLE 1 EXCHANGE RATES FOR CONVERSION TO USD 41 TABLE 2 ASIA PACIFIC: R&D INVESTMENT BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 54 TABLE 3 PUBLIC AND PRIVATE-SECTOR FUNDING FOR BIOINFORMATICS AND RELATED FIELDS 56 TABLE 4 BIOINFORMATICS MARKET: PORTER’S FIVE FORCES 68 TABLE 5 BIOINFORMATICS MARKET: ROLE IN ECOSYSTEM 74 TABLE 6 INDICATIVE PRICING IN BIOINFORMATICS MARKET, BY OFFERING (2025) 75 TABLE 7 INDICATIVE PRICING OF SOFTWARE (NICHE POINT SOLUTIONS), BY REGION (2025) 76 TABLE 8 BIOINFORMATICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 77 TABLE 9 CASE 1: FASTER WORKFLOWS, COST-EFFICIENCY, AND SIMPLIFIED INFRASTRUCTURE 80 TABLE 10 CASE STUDY 2: COMPREHENSIVE CLINICAL EXOME ANALYSIS TO SUPPORT DIVERSE APPLICATIONS AT HENRY FORD HEALTH 81 TABLE 11 CASE STUDY 2: CHAMPIONS ONCOLOGY SCALES MULTIOMICS ANALYSIS WITH SEQERA TO ACCELERATE CANCER THERAPY DEVELOPMENT 81 TABLE 12 US ADJUSTED RECIPROCAL TARIFF RATES 83 TABLE 13 COUNTRY 83 TABLE 14 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR BIOINFORMATICS MARKET 93 TABLE 15 BIOINFORMATICS MARKET: KEY PATENTS/PATENT APPLICATIONS 95 TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 TABLE 20 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108 TABLE 21 REGULATORY SCENARIO IN NORTH AMERICA 108 TABLE 22 REGULATORY SCENARIO IN EUROPE 109 TABLE 23 REGULATORY SCENARIO IN ASIA PACIFIC 110 TABLE 24 REGULATORY SCENARIO IN LATIN AMERICA 110 TABLE 25 REGULATORY SCENARIO IN MIDDLE EAST & AFRICA 111 TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%) 115 TABLE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS 116 TABLE 28 UNMET NEEDS IN BIOINFORMATICS MARKET 118 TABLE 29 END USER EXPECTATIONS IN BIOINFORMATICS MARKET 119 TABLE 30 BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 122 TABLE 31 BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 123 TABLE 32 BIOINFORMATICS MARKET FOR SOFTWARE, BY REGION, 2024–2031(USD MILLION) 123 TABLE 33 NICHE POINT SOLUTIONS OFFERED BY KEY MARKET PLAYERS 124 TABLE 34 BIOINFORMATICS MARKET FOR NICHE POINT SOLUTIONS, BY REGION, 2024–2031(USD MILLION) 125 TABLE 35 BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 126 TABLE 36 BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 37 GENERALIZED KNOWLEDGE MANAGEMENT TOOLS OFFERED BY KEY MARKET PLAYERS 127 TABLE 38 BIOINFORMATICS MARKET FOR GENERALIZED KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024–2031 (USD MILLION) 127 TABLE 39 SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS OFFERED BY KEY MARKET PLAYERS 128 TABLE 40 BIOINFORMATICS MARKET FOR SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 41 BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 130 TABLE 42 BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 43 GENOMIC SOLUTIONS OFFERED BY KEY MARKET PLAYERS 131 TABLE 44 BIOINFORMATICS MARKET FOR GENOMIC SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 45 MULTIOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 133 TABLE 46 BIOINFORMATICS MARKET FOR MULTIOMICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 47 CHEMOINFORMATICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 134 TABLE 48 BIOINFORMATICS MARKET FOR CHEMOINFORMATICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 49 PROTEOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 135 TABLE 50 BIOINFORMATICS MARKET FOR PROTEOMICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 51 TRANSCRIPTOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 137 TABLE 52 BIOINFORMATICS MARKET FOR TRANSCRIPTOMICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 53 METABOLOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 138 TABLE 54 BIOINFORMATICS MARKET FOR METABOLOMICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 55 OTHER END-TO-END SOLUTIONS OFFERED BY KEY MARKET PLAYERS 139 TABLE 56 BIOINFORMATICS MARKET FOR OTHER END-TO-END SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 57 BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 140 TABLE 58 BIOINFORMATICS MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 59 SEQUENCING & DATA GENERATION SERVICES OFFERED BY KEY MARKET PLAYERS 141 TABLE 60 BIOINFORMATICS MARKET FOR SEQUENCING & DATA GENERATION SERVICES, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 61 DATA ANALYSIS & INTERPRETATION SERVICES OFFERED BY KEY MARKET PLAYERS 143 TABLE 62 BIOINFORMATICS MARKET FOR DATA ANALYSIS & INTERPRETATION, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 63 DRUG DISCOVERY & TARGET IDENTIFICATION OFFERED BY KEY MARKET PLAYERS 144 TABLE 64 BIOINFORMATICS MARKET FOR DRUG DISCOVERY & TARGET IDENTIFICATION, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 65 DATABASE & DATA MANAGEMENT SERVICES OFFERED BY KEY MARKET PLAYERS 145 TABLE 66 BIOINFORMATICS MARKET FOR DATABASE & DATA MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 67 CLOUD & MANAGED BIOINFORMATICS SERVICES OFFERED BY KEY MARKET PLAYERS 146 TABLE 68 BIOINFORMATICS MARKET FOR CLOUD & MANAGED BIOINFORMATICS, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 69 CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT SERVICES OFFERED BY KEY MARKET PLAYERS 147 TABLE 70 BIOINFORMATICS MARKET FOR CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 71 OTHER BIOINFORMATICS SERVICES OFFERED BY KEY MARKET PLAYERS 148 TABLE 72 BIOINFORMATICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 73 BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 151 TABLE 74 BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 152 TABLE 75 BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 76 BIOINFORMATICS MARKET FOR SEQUENCE ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 77 BIOINFORMATICS MARKET FOR VARIANT ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 78 BIOINFORMATICS MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 79 BIOINFORMATICS MARKET FOR OTHER DATA ANALYSIS FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 80 BIOINFORMATICS MARKET FOR STRUCTURAL & FUNCTIONAL ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 81 BIOINFORMATICS MARKET FOR MULTIOMICS INTEGRATION, BY REGION, 2024–2031 (USD MILLION) 157 TABLE 82 BIOINFORMATICS MARKET FOR CLINICAL INTERPRETATION, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 83 BIOINFORMATICS MARKET FOR DATA VISUALIZATION & REPORTING, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 84 BIOINFORMATICS MARKET FOR OTHER FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 160 TABLE 85 BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 162 TABLE 86 BIOINFORMATICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 87 BIOINFORMATICS MARKET FOR PRECISION MEDICINE, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 88 BIOINFORMATICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 165 TABLE 89 BIOINFORMATICS MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 90 BIOINFORMATICS MARKET FOR RESEARCH & ACADEMIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 91 BIOINFORMATICS MARKET FOR OTHER USE CASES, BY REGION, 2024–2031 (USD MILLION) 168 TABLE 92 BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 170 TABLE 93 BIOINFORMATICS MARKET FOR MEDICAL BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 171 TABLE 94 BIOINFORMATICS MARKET FOR ANIMAL BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 172 TABLE 95 BIOINFORMATICS MARKET FOR PLANT BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 96 BIOINFORMATICS MARKET FOR ENVIRONMENTAL BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 174 TABLE 97 BIOINFORMATICS MARKET FOR FORENSIC BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 98 BIOINFORMATICS MARKET FOR OTHER SECTORS, BY REGION, 2024–2031 (USD MILLION) 176 TABLE 99 BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 178 TABLE 100 BIOINFORMATICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 101 BIOINFORMATICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 180 TABLE 102 BIOINFORMATICS MARKET FOR HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 103 BIOINFORMATICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 104 BIOINFORMATICS MARKET FOR GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 184 TABLE 105 BIOINFORMATICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 106 BIOINFORMATICS MARKET, BY REGION, 2024–2031 (USD MILLION) 187 TABLE 107 NORTH AMERICA: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 108 NORTH AMERICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 189 TABLE 109 NORTH AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 110 NORTH AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 190 TABLE 111 NORTH AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 112 NORTH AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 113 NORTH AMERICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 192 TABLE 114 NORTH AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 192 TABLE 115 NORTH AMERICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 193 TABLE 116 NORTH AMERICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 193 TABLE 117 NORTH AMERICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 194 TABLE 118 US: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 195 TABLE 119 US: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 120 US: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 121 US: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 122 US: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 123 US: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 198 TABLE 124 US: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 125 US: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 199 TABLE 126 US: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 199 TABLE 127 US: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 200 TABLE 128 CANADA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 201 TABLE 129 CANADA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 130 CANADA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 131 CANADA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 132 CANADA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 133 CANADA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 204 TABLE 134 CANADA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 135 CANADA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 205 TABLE 136 CANADA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 205 TABLE 137 CANADA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 206 TABLE 138 EUROPE: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 139 EUROPE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 207 TABLE 140 EUROPE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 141 EUROPE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 142 EUROPE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 143 EUROPE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 144 EUROPE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 210 TABLE 145 EUROPE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 146 EUROPE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 211 TABLE 147 EUROPE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 211 TABLE 148 EUROPE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 212 TABLE 149 GERMANY: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 213 TABLE 150 GERMANY: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 151 GERMANY: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 152 GERMANY: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 153 GERMANY: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 154 GERMANY: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 216 TABLE 155 GERMANY: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 156 GERMANY: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 217 TABLE 157 GERMANY: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 217 TABLE 158 GERMANY: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 218 TABLE 159 UK: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 219 TABLE 160 UK: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 161 UK: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 162 UK: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 163 UK: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 164 UK: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 221 TABLE 165 UK: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 222 TABLE 166 UK: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 222 TABLE 167 UK: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 223 TABLE 168 UK: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 223 TABLE 169 FRANCE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 225 TABLE 170 FRANCE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 171 FRANCE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 225 TABLE 172 FRANCE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 173 FRANCE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 174 FRANCE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 227 TABLE 175 FRANCE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 176 FRANCE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 228 TABLE 177 FRANCE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 228 TABLE 178 FRANCE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 229 TABLE 179 ITALY: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 230 TABLE 180 ITALY: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 230 TABLE 181 ITALY: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 182 ITALY: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 231 TABLE 183 ITALY: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 232 TABLE 184 ITALY: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 232 TABLE 185 ITALY: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 186 ITALY: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 233 TABLE 187 ITALY: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 234 TABLE 188 ITALY: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 234 TABLE 189 SPAIN: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 235 TABLE 190 SPAIN: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 191 SPAIN: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 192 SPAIN: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 193 SPAIN: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 194 SPAIN: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 237 TABLE 195 SPAIN: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 196 SPAIN: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 238 TABLE 197 SPAIN: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 239 TABLE 198 SPAIN: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 239 TABLE 199 REST OF EUROPE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 240 TABLE 200 REST OF EUROPE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 201 REST OF EUROPE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 202 REST OF EUROPE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 203 REST OF EUROPE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 204 REST OF EUROPE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 243 TABLE 205 REST OF EUROPE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 206 REST OF EUROPE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 244 TABLE 207 REST OF EUROPE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 244 TABLE 208 REST OF EUROPE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 245 TABLE 209 ASIA PACIFIC: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 210 ASIA PACIFIC: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 247 TABLE 211 ASIA PACIFIC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 212 ASIA PACIFIC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 213 ASIA PACIFIC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 214 ASIA PACIFIC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 215 ASIA PACIFIC: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 249 TABLE 216 ASIA PACIFIC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 217 ASIA PACIFIC: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 250 TABLE 218 ASIA PACIFIC: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 251 TABLE 219 ASIA PACIFIC: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 251 TABLE 220 CHINA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 253 TABLE 221 CHINA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 222 CHINA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 223 CHINA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 224 CHINA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 225 CHINA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 255 TABLE 226 CHINA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 227 CHINA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 256 TABLE 228 CHINA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 256 TABLE 229 CHINA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 257 TABLE 230 JAPAN: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 258 TABLE 231 JAPAN: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 232 JAPAN: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 233 JAPAN: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 234 JAPAN: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 235 JAPAN: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 260 TABLE 236 JAPAN: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 237 JAPAN: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 261 TABLE 238 JAPAN: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 262 TABLE 239 JAPAN: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 262 TABLE 240 INDIA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 263 TABLE 241 INDIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 242 INDIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 243 INDIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 244 INDIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 245 INDIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 265 TABLE 246 INDIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 247 INDIA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 266 TABLE 248 INDIA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 267 TABLE 249 INDIA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 267 TABLE 250 AUSTRALIA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 268 TABLE 251 AUSTRALIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 252 AUSTRALIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 253 AUSTRALIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 254 AUSTRALIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 255 AUSTRALIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 271 TABLE 256 AUSTRALIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 257 AUSTRALIA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 272 TABLE 258 AUSTRALIA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 272 TABLE 259 AUSTRALIA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 273 TABLE 260 SOUTH KOREA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 274 TABLE 261 SOUTH KOREA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 274 TABLE 262 SOUTH KOREA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 263 SOUTH KOREA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 264 SOUTH KOREA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 265 SOUTH KOREA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 276 TABLE 266 SOUTH KOREA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 267 SOUTH KOREA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 277 TABLE 268 SOUTH KOREA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 278 TABLE 269 SOUTH KOREA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 278 TABLE 270 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 279 TABLE 271 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 272 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 273 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 274 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 275 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 282 TABLE 276 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 277 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 283 TABLE 278 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 283 TABLE 279 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 284 TABLE 280 LATIN AMERICA: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 285 TABLE 281 LATIN AMERICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 286 TABLE 282 LATIN AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 283 LATIN AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 284 LATIN AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 285 LATIN AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 286 LATIN AMERICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 288 TABLE 287 LATIN AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 288 LATIN AMERICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 289 TABLE 289 LATIN AMERICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 289 TABLE 290 LATIN AMERICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 290 TABLE 291 BRAZIL: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 291 TABLE 292 BRAZIL: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 293 BRAZIL: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 294 BRAZIL: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 295 BRAZIL: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 296 BRAZIL: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 293 TABLE 297 BRAZIL: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 298 BRAZIL: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 294 TABLE 299 BRAZIL: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 295 TABLE 300 BRAZIL: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 295 TABLE 301 MEXICO: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 297 TABLE 302 MEXICO: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 303 MEXICO: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 304 MEXICO: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 305 MEXICO: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 306 MEXICO: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 299 TABLE 307 MEXICO: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 308 MEXICO: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 300 TABLE 309 MEXICO: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 300 TABLE 310 MEXICO: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 301 TABLE 311 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 302 TABLE 312 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 313 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 314 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 315 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 316 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 304 TABLE 317 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 318 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 305 TABLE 319 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 306 TABLE 320 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 306 TABLE 321 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 308 TABLE 322 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 308 TABLE 323 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 324 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 325 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 326 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 327 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 310 TABLE 328 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 329 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 311 TABLE 330 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 312 TABLE 331 MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 312 TABLE 332 GCC COUNTRIES: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 313 TABLE 333 GCC COUNTRIES: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 314 TABLE 334 GCC COUNTRIES: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 335 GCC COUNTRIES: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 336 GCC COUNTRIES: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 337 GCC COUNTRIES: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 338 GCC COUNTRIES: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 316 TABLE 339 GCC COUNTRIES: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 340 GCC COUNTRIES: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 317 TABLE 341 GCC COUNTRIES: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 317 TABLE 342 GCC COUNTRIES: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 343 SAUDI ARABIA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 319 TABLE 344 SAUDI ARABIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 345 SAUDI ARABIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 346 SAUDI ARABIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 347 SAUDI ARABIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 348 SAUDI ARABIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 321 TABLE 349 SAUDI ARABIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 322 TABLE 350 SAUDI ARABIA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 322 TABLE 351 SAUDI ARABIA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 323 TABLE 352 SAUDI ARABIA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 323 TABLE 353 UAE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 325 TABLE 354 UAE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 355 UAE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 356 UAE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 357 UAE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 358 UAE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 327 TABLE 359 UAE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 327 TABLE 360 UAE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 328 TABLE 361 UAE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 328 TABLE 362 UAE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 329 TABLE 363 REST OF GCC: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 330 TABLE 364 REST OF GCC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 365 REST OF GCC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 366 REST OF GCC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 367 REST OF GCC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 368 REST OF GCC: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 332 TABLE 369 REST OF GCC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 370 REST OF GCC: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 333 TABLE 371 REST OF GCC: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 333 TABLE 372 REST OF GCC: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 334 TABLE 373 SOUTH AFRICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 335 TABLE 374 SOUTH AFRICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 375 SOUTH AFRICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 376 SOUTH AFRICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 377 SOUTH AFRICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 378 SOUTH AFRICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 337 TABLE 379 SOUTH AFRICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 380 SOUTH AFRICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 338 TABLE 381 SOUTH AFRICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 338 TABLE 382 SOUTH AFRICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 339 TABLE 383 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 340 TABLE 384 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 385 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 386 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 341 TABLE 387 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 341 TABLE 388 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 342 TABLE 389 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 390 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 343 TABLE 391 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 343 TABLE 392 REST OF MIDDLE EAST & AFRICA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 344 TABLE 393 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 345 TABLE 394 BIOINFORMATICS MARKET: DEGREE OF COMPETITION 349 TABLE 395 BIOINFORMATICS MARKET: REGION FOOTPRINT 357 TABLE 396 BIOINFORMATICS MARKET: OFFERING FOOTPRINT 358 TABLE 397 BIOINFORMATICS MARKET: FUNCTION FOOTPRINT 359 TABLE 398 BIOINFORMATICS MARKET: USE CASE FOOTPRINT 360 TABLE 399 BIOINFORMATICS MARKET: END USER FOOTPRINT 361 TABLE 400 BIOINFORMATICS MARKET: LIST OF STARTUPS/SMES 364 TABLE 401 BIOINFORMATICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 365 TABLE 402 BIOINFORMATICS MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, 2023–2026 366 TABLE 403 BIOINFORMATICS MARKET: DEALS, 2023–2026 367 TABLE 404 BIOINFORMATICS MARKET: EXPANSIONS, 2023–2026 369 TABLE 405 BIOINFORMATICS MARKET: OTHER DEVELOPMENTS, 2023–2026 370 TABLE 406 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 371 TABLE 407 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED 373 TABLE 408 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026 375 TABLE 409 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023−JULY 2026 375 TABLE 410 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–JULY 2026 376 TABLE 411 ILLUMINA, INC.: COMPANY OVERVIEW 378 TABLE 412 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 379 TABLE 413 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026 380 TABLE 414 ILLUMINA, INC.: DEALS, JANUARY 2023–JULY 2026 381 TABLE 415 ILLUMINA, INC.: EXPANSIONS, JANUARY 2023–JULY 2026 384 TABLE 416 QIAGEN N.V.: COMPANY OVERVIEW 386 TABLE 417 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED 387 TABLE 418 QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–JULY 2026 389 TABLE 419 QIAGEN N.V.: DEALS, JANUARY 2023–JULY 2026 390 TABLE 420 QIAGEN N.V.: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 391 TABLE 421 QIAGEN N.V.: EXPANSIONS, JANUARY 2023–JULY 2026 392 TABLE 422 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 393 TABLE 423 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 394 TABLE 424 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023−JULY 2026 395 TABLE 425 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 397 TABLE 426 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 398 TABLE 427 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026 399 TABLE 428 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–JULY 2026 399 TABLE 429 F. HOFFMANN-LA ROCHE LTD.: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 400 TABLE 430 REVVITY, INC.: COMPANY OVERVIEW 401 TABLE 431 REVVITY, INC.: PRODUCTS/SERVICES OFFERED 402 TABLE 432 REVVITY, INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026 403 TABLE 433 REVVITY, INC.: DEALS, JANUARY 2023–JULY 2026 404 TABLE 434 REVVITY: EXPANSIONS, JANUARY 2023–JULY 2026 405 TABLE 435 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 406 TABLE 436 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED 407 TABLE 437 EUROFINS SCIENTIFIC: DEALS, JANUARY 2023–JULY 2026 408 TABLE 438 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023–JULY 2026 409 TABLE 439 BGI GENOMICS: COMPANY OVERVIEW 410 TABLE 440 BGI GENOMICS: PRODUCTS/SERVICES OFFERED 410 TABLE 441 BGI GENOMICS: DEALS, JANUARY 2023–JULY 2026 412 TABLE 442 WATERS CORPORATION: COMPANY OVERVIEW 413 TABLE 443 WATERS CORPORATION: PRODUCTS/SERVICES OFFERED 414 TABLE 444 DNANEXUS, INC. COMPANY OVERVIEW 415 TABLE 445 DNANEXUS, INC.: PRODUCTS/SERVICES OFFERED 415 TABLE 446 DNANEXUS, INC.: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026 416 TABLE 447 DNANEXUS, INC.: DEALS, JANUARY 2023–JULY 2026 417 TABLE 448 DNANEXUS, INC.: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 417 TABLE 449 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW 418 TABLE 450 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES OFFERED 419 TABLE 451 OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2023–JULY 2026 420 TABLE 452 OXFORD NANOPORE TECHNOLOGIES PLC: EXPANSIONS, JANUARY 2023- JULY 2026 421 TABLE 453 10X GENOMICS: COMPANY OVERVIEW 422 TABLE 454 10X GENOMICS: PRODUCTS/SERVICES OFFERED 423 TABLE 455 10X GENOMICS: DEALS, JANUARY 2023–JULY 2026 424 TABLE 456 PACBIO: COMPANY OVERVIEW 426 TABLE 457 PACBIO: PRODUCTS/SERVICES OFFERED 427 TABLE 458 PACBIO: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026 428 TABLE 459 PACBIO: DEALS, JANUARY 2023–JULY 2026 428 TABLE 460 PACBIO: EXPANSIONS, JANUARY 2023–JULY 2026 429 TABLE 461 SIEMENS AG: COMPANY OVERVIEW 430 TABLE 462 SIEMENS AG: PRODUCTS/SERVICES OFFERED 431 TABLE 463 SIEMENS AG: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026 432 TABLE 464 SIEMENS AG: DEALS, JANUARY 2023–JULY 2026 433 TABLE 465 SIEMENS AG: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 434 TABLE 466 SOPHIA GENETICS: COMPANY OVERVIEW 435 TABLE 467 SOPHIA GENETICS: PRODUCTS/SERVICES OFFERED 436 TABLE 468 SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2023–JULY 2026 437 TABLE 469 SOPHIA GENETICS: DEALS, JANUARY 2023–JULY 2026 437 TABLE 470 SOPHIA GENETICS: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 439 TABLE 471 EXCELRA: COMPANY OVERVIEW 440 TABLE 472 EXCELRA: PRODUCTS/SERVICES OFFERED 440 TABLE 473 EXCELRA: PRODUCT ENHANCEMENT, JANUARY 2023–JULY 2026 441 TABLE 474 EXCELRA: DEALS, JANUARY 2023–JULY 2026 442 TABLE 475 GENEWIZ (AZENTA LIFE SCIENCES): COMPANY OVERVIEW 443 TABLE 476 GENEWIZ (AZENTA LIFE SCIENCES): PRODUCTS/SERVICES OFFERED 444 TABLE 477 GENEWIZ (AZENTA LIFE SCIENCES): DEALS, JANUARY 2023–JULY 2026 445 TABLE 478 GENEWIZ (AZENTA LIFE SCIENCES): OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 445 TABLE 479 ONTOFORCE: COMPANY OVERVIEW 446 TABLE 480 ONTOFORCE: PRODUCTS/SERVICES OFFERED 446 TABLE 481 ONTOFORCE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–JULY 2026 447 TABLE 482 ONTOFORCE: DEALS, JANUARY 2023–JULY 2026 448 TABLE 483 VELSERA INC.: COMPANY OVERVIEW 449 TABLE 484 VELSERA INC.: PRODUCTS/SERVICES OFFERED 449 TABLE 485 VELSERA INC.: DEALS, JANUARY 2023–JULY 2026 450 TABLE 486 SEQERA: COMPANY OVERVIEW 451 TABLE 487 SEQERA: PRODUCTS/SERVICES OFFERED 451 TABLE 488 SEQERA: PRODUCT LAUNCHES & ENHANCEMENT, JANUARY 2023–JULY 2026 452 TABLE 489 SEQERA: DEALS, JANUARY 2023–JULY 2026 453 TABLE 490 SEQERA: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 453 TABLE 491 RISK ASSESSMENT: BIOINFORMATICS MARKET 476 FIGURE 1 MARKET SCENARIO 44 FIGURE 2 GLOBAL BIOINFORMATICS MARKET, 2024–2031 44 FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOINFORMATICS MARKET, 2023–2026 45 FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF BIOINFORMATICS MARKET 46 FIGURE 5 HIGH-GROWTH SEGMENTS IN BIOINFORMATICS MARKET, 2026–2031 47 FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOINFORMATICS MARKET DURING FORECAST PERIOD 48 FIGURE 7 INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 49 FIGURE 8 SOFTWARE ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025 50 FIGURE 9 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50 FIGURE 10 BIOINFORMATICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51 FIGURE 11 GLOBAL CANCER INCIDENCE, 2008−2030 53 FIGURE 12 FDA-APPROVED PERSONALIZED MEDICINES, 2015−2024 54 FIGURE 13 BIOINFORMATICS MARKET: PORTER’S FIVE FORCES ANALYSIS 68 FIGURE 14 BIOINFORMATICS MARKET: VALUE CHAIN ANALYSIS 72 FIGURE 15 ECOSYSTEM ANALYSIS 73 FIGURE 16 REVENUE SHIFT IN BIOINFORMATICS MARKET 79 FIGURE 17 RECENT FUNDING OF PLAYERS IN BIOINFORMATICS MARKET 80 FIGURE 18 PATENT PUBLICATION TRENDS IN BIOINFORMATICS MARKET, 2015–2026 93 FIGURE 19 JURISDICTION AND TOP APPLICANT ANALYSIS FOR BIOINFORMATICS MARKET 93 FIGURE 20 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) IN BIOINFORMATICS MARKET (JANUARY 2015–JULY 2026) 94 FIGURE 21 MARKET POTENTIAL OF GENERATIVE AI IN ENHANCING BIOINFORMATICS 98 FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 100 FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 114 FIGURE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 115 FIGURE 25 NORTH AMERICA: BIOINFORMATICS MARKET SNAPSHOT 188 FIGURE 26 ASIA PACIFIC: BIOINFORMATICS MARKET SNAPSHOT 246 FIGURE 27 REVENUE ANALYSIS OF TOP LISTED/PUBLIC PLAYERS, 2021–2025 (USD MILLION) 348 FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 349 FIGURE 29 BRAND COMPARISON 352 FIGURE 30 EV/EBITDA OF KEY VENDORS 353 FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS 353 FIGURE 32 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 355 FIGURE 33 BIOINFORMATICS MARKET: COMPANY FOOTPRINT 356 FIGURE 34 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 363 FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 372 FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 379 FIGURE 37 QIAGEN N.V.: COMPANY SNAPSHOT (2025) 387 FIGURE 38 GILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 394 FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 398 FIGURE 40 REVVITY, INC.: COMPANY SNAPSHOT (2025) 402 FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 407 FIGURE 42 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 414 FIGURE 43 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025) 419 FIGURE 44 10X GENOMICS: COMPANY SNAPSHOT (2025) 423 FIGURE 45 PACBIO: COMPANY SNAPSHOT (2025) 427 FIGURE 46 SIEMENS AG: COMPANY SNAPSHOT (2025) 431 FIGURE 47 SOPHIA GENETICS: COMPANY SNAPSHOT (2025) 436 FIGURE 48 AZENTA INC.: COMPANY SNAPSHOT (2025) 444 FIGURE 49 RESEARCH DESIGN 460 FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 465 FIGURE 51 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 467 FIGURE 52 BOTTOM-UP APPROACH 468 FIGURE 53 TOP-DOWN APPROACH 469 FIGURE 54 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF BIOINFORMATICS MARKET 470 FIGURE 55 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 471 FIGURE 56 DATA TRIANGULATION METHODOLOGY 474

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們